公开(公告)号：US20240034816A1

公开(公告)日：2024-02-01

申请号：US18469947

申请日：2023-09-19

Applicant: SANOFI ,  INNATE PHARMA

Inventor： Nicolas GOURDIN ,  Laurent GAUTHIER ,  Alexandre TANG ,  Marielle CHIRON ,  Angela VIRONE-ODDOS ,  Alessandro MASIERO ,  Jochen BENINGA ,  Ingo FOCKEN ,  Sambasiva RAO ,  Yanfeng ZHOU ,  Leila SEVIGNY

IPC: C07K16/46 ,  C12N15/63 ,  A61P35/00

CPC classification number: C07K16/468 ,  C12N15/63 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/41 ,  C07K2317/14 ,  C07K2317/31

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

公开(公告)号：US20230099801A1

公开(公告)日：2023-03-30

申请号：US17876164

申请日：2022-07-28

Applicant: INNATE PHARMA

Inventor： Stéphanie CHANTEUX ,  Nicolas GOURDIN ,  Carine PATUREL ,  Ivan PERROT ,  Benjamin ROSSI

IPC: C07K16/40 ,  C07K16/28 ,  A61K39/00 ,  C12N9/14 ,  A61P35/00 ,  A61K9/00 ,  G01N33/574

Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.

公开(公告)号：US20190218304A1

公开(公告)日：2019-07-18

申请号：US16370789

申请日：2019-03-29

Applicant: INNATE PHARMA

Inventor： Stéphanie CHANTEUX ,  Nicolas GOURDIN ,  Carine PATUREL ,  Ivan PERROT ,  Benjamin ROSSI

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/40 ,  A61K39/395 ,  A61K31/282

CPC classification number: C07K16/2896 ,  A61K31/282 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/40 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.